Unlike SGLT-2 inhibitors, semaglutide does not alter urinary glucose levels or create conditions that directly promote bacterial growth in the urinary tract
The label is marketing
Furthermore, the involvement of CHAC1 in non-malignant diseases, such as diabetes, liver injury, and respiratory disorders, adds complexity, as its therapeutic modulation could potentially worsen these conditions by disrupting GSHmetabolism and increasing oxidative stress
Liability Disclaimer In no event shall the publisher, its officers, employees, or affiliates be liable for any direct, indirect, incidental, special, or consequential damages arising from or in connection with the use of the information contained in this publication